1. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
by Tomer M. Mark, Peter A. Forsberg, Adriana C. Rossi, Roger N. Pearse, Karen A. Pekle, Arthur Perry, Angelique Boyer, Linda Tegnestam, David Jayabalan, Morton Coleman, and Ruben Niesvizky
BloodAdv
Volume 3(4):
February 26, 2019
© 2019 by The American Society of Hematology

2. Tomer M. Mark et al. Blood Adv 2019;3:603-611
© 2019 by The American Society of Hematology

3. Responses over time to ClaPD.
Responses over time to ClaPD. Responses by treatment cycle in patients who were lenalidomide refractory (A), bortezomib refractory (B), and refractory to both lenalidomide and bortezomib (double refractory) (C).
Tomer M. Mark et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology

4. Survival outcomes.
Survival outcomes. (A) PFS. Median PFS was 7.67 months (95% CI, 5.6, 9.5). (B) OS. Median OS was 19.2 months (95% CI, 14.2, 26.7).
Tomer M. Mark et al. Blood Adv 2019;3:
© 2019 by The American Society of Hematology